BLUEJET

Management highlighted FY26 as a foundational year, with destocking in the PI/API segment largely behind, leading to improved visibility and confirmed orders. They expect double-digit growth in contrast media for FY27, supported by new product launches. A significant long-term growth platform is underway with INR1,000 crores capex for the Vizag greenfield project over 3 years, with Phase 1 production starting in H2 FY27. An R&D center in Hyderabad (INR40 crores) will focus on new chemistry platforms, including peptides. The company is debt-free with INR400 crores in liquid assets.

Blue Jet Healthcare Limited announced an Extra-Ordinary General Meeting (EGM) to be held on June 17, 2026, through Video Conferencing. The EGM will seek shareholder approval to raise funds up to ₹10,000 million (₹1000 Crores) through the issuance of Equity Shares and/or other Eligible Securities, which may include Qualified Institutions Placement (QIP).

Blue Jet Healthcare Limited announced the submission of the audio recording of its earnings conference call, held to discuss the financial results for the quarter and financial year ended March 31, 2026. The recording is accessible on the company's website as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

New Filing detected. See link for details.

The Board of Directors of Blue Jet Healthcare Limited approved Audited Standalone Financial Results for Q4 FY26, reporting Revenue of ₹340.45 Cr (▲44.40% YoY), EBITDA of ₹139.97 Cr (▲96.40% YoY), and PAT of ₹110.10 Cr (▲71.10% YoY). EBITDA Margin expanded by 1074 bps to 41.11%. The Board also recommended a final dividend of ₹1.2 per share for FY26 and approved a proposal to raise funds up to ₹1,000 Cr through various instruments, subject to EGM approval on June 17, 2026.

Standalone Revenue ₹3,404.45Mn vs ₹2,346.68Mn (▲44.15% YoY), EBITDA ₹1,409.68Mn vs ₹712.67Mn (▲97.80% YoY), PAT ₹1,100.95Mn vs ₹643.44Mn (▲71.10% YoY) for the quarter ended March 31, 2026. EBITDA Margin 41.41% vs 30.37% (▲1104bps). The Board also recommended a final dividend of ₹1.2 per equity share for FY26 and proposed to raise funds up to ₹10,000 million (₹1,000 Cr) through various instruments, subject to shareholder approval.

New Filing detected. See link for details.